PDCD1 and hepatocellular carcinoma: On May 29, 2020, the FDA approved programmed cell death protein 1 (PD1)/programmed cell death 1 ligand 1 (PD-L1) immune checkpoint inhibitor atezolizumab in combination with angiogenesis growth factor (VEGF) inhibitor bevacizumab for patients with unresectable or metastatic HCC without prior systemic therapy.